Femasys
NASDAQ: FEMYSuwanee, US · Delaware corporation · 59 employees on LinkedIn
Find your way into Femasys
67 people in our graph share verified history with the Femasys team — schools, employers, funds. One of them is your warm intro.
Michael Eisenbergunlockedknows Dov Elefant · together at Yeshiva University (overlapped)
×11knows the team · via Yeshiva University
Femasys develops office-based medical devices for women's healthcare, including first-line fertility treatments (FemaSeed, FemHSG catheter) delivered by OB/GYNs and fertility specialists, and a minimally invasive permanent birth control system (FemBloc). Its products aim to provide more affordable, less invasive alternatives to IVF and surgical contraception.
Founders & leadership
KL
Kathy Lee-SepsickFounder
DE
Dov ElefantinChief Financial OfficerDov Elefant is an executive officer at Femasys with over 30 years of finance and accounting experience in public and private companies, including expertise in SEC reporting, financial planning, fundraising, and mergers and acquisitions.
DC
Daniel CurrieExecutive
JS
Jeremy SipposExecutive
JC
John CanninngExecutive
JM
Jeffrey MifekExecutive
Board
JS
Joshua SilvermanBoard director
EU
Edward UzialkoBoard director
AM
Alistair MilnesBoard director
CL
Charles LarsenBoard director
JQ
John Q. AdamsBoard director
ER
Edward R., Jr. UzialkoBoard director
Reported raises · per SEC filings
Form D private placements$98.3M disclosed across 8 rounds · 2015–2026
▶$30MraisedAug 2026 · 41 investors · BiotechnologyRule 506(b)
▶$30MraisedAug 2026 · 41 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kathy Lee-SepsickExecutive Officer, Director
- Dov ElefantExecutive Officer
- Charles LarsenDirector
- Alistair MilnesDirector
- Kenneth EichenbaumDirector
- Edward R. UzialkoDirector
- Jeremy SipposExecutive Officer
- John CanninngExecutive Officer
- Jeffrey MifekExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedNov 2025 · 12 investors · BiotechnologyRule 506(b)
▶$8MraisedNov 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alistair MilnesDirector
- Charles LarsenDirector
- Kathy Lee-SepsickExecutive Officer, Director
- Dov ElefantExecutive Officer
- Joshua SilvermanDirector
- Edward R. UzialkoDirector
- Offering amount
- $12M
- Amount sold
- $8M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedJun 2025 · 6 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJun 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joshua SilvermanDirector
- Kathy Lee-SepsickExecutive Officer, Director
- Dov ElefantExecutive Officer
- Edward UzialkoDirector
- Daniel CurrieExecutive Officer
- Alistair MilnesDirector
- Charles LarsenDirector
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- Sales commissions
- $51.5K
- Placement agents
- JonesTrading Institutional Services LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.8MraisedNov 2023 · 4 investors · BiotechnologyRule 506(b)
▶$6.8MraisedNov 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alistair MilnesDirector
- Daniel CurrieExecutive Officer
- Dov ElefantExecutive Officer
- Edward UzialkoDirector
- Joshua SilvermanDirector
- Charles LarsenDirector
- Kathy Lee-SepsickExecutive Officer, Director
- Offering amount
- $6.8M
- Amount sold
- $6.8M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJan 2017 · 8 investors · BiotechnologyRule 506(b)
▶$4MraisedJan 2017 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles LarsenDirector
- Fred AslanDirector
- John DyettDirector
- Edward UzialkoDirector
- William WitteDirector
- Kathy Lee-SepsickExecutive Officer, Director
- John AdamsDirector
- Offering amount
- $4M
- Amount sold
- $4M
- Sales commissions
- $200K
- Placement agents
- Salem Partners LLC
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$36.6MraisedDec 2016 · 18 investors · BiotechnologyRule 506(b)
▶$36.6MraisedDec 2016 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William WitteDirector
- Kathy Lee-SepsickExecutive Officer, Director
- Fred AslanDirector
- Charles LarsenDirector
- John DyettDirector
- John AdamsDirector
- Edward UzialkoDirector
- Offering amount
- $36.6M
- Amount sold
- $36.6M
- Sales commissions
- $2M
- Placement agents
- Salem Partners LLC
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedAug 2016 · 19 investors · BiotechnologyRule 506(b)
▶$3.3MraisedAug 2016 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles LarsenDirector
- Edward UzialkoDirector
- Kathy Lee-SepsickExecutive Officer, Director
- Fred AslanDirector
- John AdamsDirector
- Offering amount
- $4M
- Amount sold
- $3.3M
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedApr 2015 · 3 investors · Other Health CareRule 506(b)
▶$8MraisedApr 2015 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kathy Lee-SepsickDirector
- John Q. AdamsDirector
- Edward R., Jr. UzialkoDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$152.9Mvaluation at IPOJun 2021 · $13.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 7
by search overlap
Seeking Alpha17 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Public15 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Robinhood15 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits15 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TradingView15 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Simply Wall St14 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Perplexity13 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with Femasys for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Femasys narrows loss, raises $30M to fund pipeline | FEMY Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Femasys do?
- Femasys develops office-based medical devices for women's healthcare, including first-line fertility treatments (FemaSeed, FemHSG catheter) delivered by OB/GYNs and fertility specialists, and a minimally invasive permanent birth control system (FemBloc). Its products aim to provide more affordable, less invasive alternatives to IVF and surgical contraception.
- Who founded Femasys?
- Femasys was founded by Kathy Lee-Sepsick.
- How much funding has Femasys raised?
- Femasys has disclosed $98.3M raised across 8 rounds.
- Where is Femasys headquartered?
- Femasys is headquartered in Suwanee, US.